Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab lead-in or concurrent nivolumab with carboplatin + paclitaxel, and nivolumab + relatlimab combinations in early triple-negative breast cancer
ACTRN12619001308189Phase 2Recruiting
- Sponsor
- Breast Cancer Trials
- Start
- Jul 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of nivolumab, relatlimab, carboplatin and paclitaxel in triple-negative breast cancer (TNBC) and breast cancer (3 arms), sponsored by Breast Cancer Trials. Primary endpoint: Pathological complete response in breast and nodes. Started Jul 2020; status: recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on ACTRN12619001308189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001308189.